COMMUNIQUÉS West-GlobeNewswire

Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets
22/10/2025
– FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream pathways compared to sotorasib – – FMC-220 potently and selectively restored p53 tumor [...]
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
22/10/2025
REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
22/10/2025
Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg [...]
EmblemHealth Celebrating Strong Leadership in Challenging Times
22/10/2025
EmblemHealth Hosts Annual Heroes of Labor Awards NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmblemHealth, a not-for-profit health plan dedicated to its community mission, and LaborPress, New York’s top source for daily [...]
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
22/10/2025
--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
22/10/2025
Company to conduct 1x1 meetings with investors on Wednesday, November 12th NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical [...]
ADARx Pharmaceuticals Announces First Patient Dosed in Phase 3 STOP-HAE Clinical Trial and Orphan Drug Designation for ADX-324, a Long-Acting siRNA in Development for the Prophylactic Treatment of Hereditary Angioedema (HAE)
22/10/2025
– Next-generation siRNA therapeutic candidate with the potential for twice-yearly dosing – SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company [...]
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
22/10/2025
Watch the "What This Means" video here Featuring the Company’s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), ( [...]
Akari Therapeutics Announces Launch of CEO Corner Platform
22/10/2025
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access [...]
Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause
22/10/2025
Global employers can now empower their workforces with comprehensive women’s health benefits, supported by localized expertise NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc . (Nasdaq: PGNY), a global leader [...]
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
22/10/2025
MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
22/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease [...]
Branded Legacy, Inc. (OTC: BLEG) Advances Life-Saving Innovation with FDA Pre-ANDA Briefing for Revolutionary Intranasal Naloxone Spray
22/10/2025
Pioneering Cost-Effective, Scalable Solutions to Combat the Global Opioid Crisis with Proprietary Air-Driven Delivery Technology VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, [...]
Fangzhou Unveils “AI + Weight Management” Innovation at China’s Inaugural National-Level Weight Management Symposium in Beijing
22/10/2025
BEIJING, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Healthy China: AI + Weight Management" Innovation Symposium was held at the National People's Congress Conference Center. The event was guided by the China Food and Drug [...]
UFC® and Smith+Nephew announce multi-year extension of partnership
22/10/2025
Smith+Nephew to continue as UFC’s Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world’s premier mixed martial arts organization, have [...]
L'usine de médicaments stériles Curia nommée fabricant de l'année dans le Massachusetts
22/10/2025
ALBANY, N.Y., 22 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), une organisation leader dans la recherche, le développement et la fabrication sous contrat, a annoncé aujourd'hui que son usine de produits [...]
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million
22/10/2025
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
Back to Life with Resuscitec’s CARL® Groundbreaking ECPR System – Nominated for the Prix Galien USA 2025 Award
22/10/2025
Resuscitec introduces a novel medical system that increases survival rates in cardiac arrest more than fivefold compared to the current standard of care – it brings patients back to life with no brain damage even after [...]
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
22/10/2025
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in [...]

Pages